Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

Published:2016-08 Issue:8 Volume:17 Page:1127-1136
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Mateos María-Victoria,Hernández Miguel-Teodoro,Giraldo Pilar,de la Rubia Javier,de Arriba Felipe,Corral Lucía López,Rosiñol Laura,Paiva Bruno,Palomera Luis,Bargay Joan,Oriol Albert,Prosper Felipe,López Javier,Arguiñano José-María,Quintana Nuria,García José-Luis,Bladé Joan,Lahuerta Juan-José,Miguel Jesús-F San

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group;Br J Haematol,2003

2. Smoldering multiple myeloma;Mateos;Hematol Oncol,2015

3. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma;Kyle;N Engl J Med,2007

4. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells;Perez-Persona;Blood,2007

5. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma;Rajkumar;Lancet Oncol,2014

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How to Identify and Manage High-Risk Smoldering Multiple Myeloma;Current Oncology Reports;2024-08-23

2. Early Detection of Precursor Diseases of Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-08

3. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance;Journal of Clinical Oncology;2024-07-22

4. Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions;Pharmaceuticals;2024-07-06

5. The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR);British Journal of Haematology;2024-07-04